Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Cash: 2011-2025

Historic Change in Cash for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$28.9 million.

  • Adma Biologics' Change in Cash fell 1780.29% to -$28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.3 million, marking a year-over-year decrease of 301.77%. This contributed to the annual value of $51.8 million for FY2024, which is 247.27% up from last year.
  • Per Adma Biologics' latest filing, its Change in Cash stood at -$28.9 million for Q3 2025, which was down 254.88% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Change in Cash registered a high of $51.6 million during Q4 2022, and its lowest value of -$31.5 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Cash was -$6.0 million (2024), whereas its average is -$2.3 million.
  • Per our database at Business Quant, Adma Biologics' Change in Cash surged by 741.44% in 2024 and then plummeted by 1,780.29% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Change in Cash stood at $16.7 million in 2021, then soared by 209.48% to $51.6 million in 2022, then slumped by 144.18% to -$22.8 million in 2023, then spiked by 172.09% to $16.4 million in 2024, then crashed by 1,780.29% to -$28.9 million in 2025.
  • Its Change in Cash was -$28.9 million in Q3 2025, compared to $18.7 million in Q2 2025 and -$31.5 million in Q1 2025.